- Home
- NIU vs EPRX Comparison
NIU vs EPRX Comparison
Compare NIU & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIU
- EPRX
- Stock Information
- Founded
- NIU 2014
- EPRX 2011
- Country
- NIU China
- EPRX Canada
- Employees
- NIU N/A
- EPRX N/A
- Industry
- NIU Auto Manufacturing
- EPRX
- Sector
- NIU Consumer Discretionary
- EPRX
- Exchange
- NIU Nasdaq
- EPRX NYSE
- Market Cap
- NIU 132.7M
- EPRX 109.7M
- IPO Year
- NIU 2018
- EPRX N/A
- Fundamental
- Price
- NIU $2.06
- EPRX $3.07
- Analyst Decision
- NIU
- EPRX Strong Buy
- Analyst Count
- NIU 0
- EPRX 1
- Target Price
- NIU N/A
- EPRX $9.00
- AVG Volume (30 Days)
- NIU 309.0K
- EPRX 5.7K
- Earning Date
- NIU 03-17-2025
- EPRX 02-11-2025
- Dividend Yield
- NIU N/A
- EPRX N/A
- EPS Growth
- NIU N/A
- EPRX N/A
- EPS
- NIU N/A
- EPRX N/A
- Revenue
- NIU $420,244,416.00
- EPRX N/A
- Revenue This Year
- NIU $16.60
- EPRX N/A
- Revenue Next Year
- NIU $24.42
- EPRX N/A
- P/E Ratio
- NIU N/A
- EPRX N/A
- Revenue Growth
- NIU 5.83
- EPRX N/A
- 52 Week Low
- NIU $1.60
- EPRX $2.20
- 52 Week High
- NIU $3.50
- EPRX $4.08
- Technical
- Relative Strength Index (RSI)
- NIU 61.16
- EPRX N/A
- Support Level
- NIU $1.94
- EPRX N/A
- Resistance Level
- NIU $1.98
- EPRX N/A
- Average True Range (ATR)
- NIU 0.09
- EPRX 0.00
- MACD
- NIU 0.02
- EPRX 0.00
- Stochastic Oscillator
- NIU 94.74
- EPRX 0.00
About NIU Niu Technologies
Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, moped and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.